Inovio wins prestigious Edward Jenner Poster Award for cervical cancer vaccine research

Inovio Pharmaceuticals (AMEX:INO) won the Edward Jenner Poster Award First Prize for its research to develop a therapeutic, synthetic vaccine for cancer.

Read more »

Advanced Cell receives green light from independent monitoring board to move forward with US trials

Advanced Cell Technology (OTCBB:ACTC) has received approval to move forward with enrolling and treating the next set of patients.

Read more »

QLT receives two fast track designations for degenerative eye disease drug

QLT (TSE:QLT) (NASDAQ:QLTI) announced Wednesday it received two fast track designations from the U.S. FDA

Read more »

NanoViricides Reports Positive Anti-viral Effect of HIV Drug

NanoViricides’ anti-HIV drug candidate, HIVCide, achieved a positive, long-term effect with fewer and weaker doses than the traditional anti-retroviral combination therapy.

Read more »

Bacterin Receives $15 Million Credit Facility

Bacterin International Holdings (AMEX:BONE) announced Tuesday it secured a 42 month-long, $15 million credit facility with MidCap Financial LLC and Silicon Valley Bank.

Read more »

IntelliCell BioSciences To Open Adipose Tissue Processing Center in Houston

IntelliCell BioSciences, Inc. (OTCQB: SVFC), maker of stromal vascular fraction that contains adipose derived adult stem cells opens new processing center in Houston, Texas.

Read more »

Bio-Rad receives pre-market approval for HIV test from FDA

Bio-Rad Laboratories (NYSE:BIO) announced Monday it received FDA premarket approval for its fourth generation human immunodeficiency virus (HIV) diagnostic test.

Read more »

Drug maker GlaxoSmithKline receives upbeat results in Promacta phase three study

Biotech company Ligand Pharmaceuticals Inc. reported Tuesday that its partner GlaxoSmithKline received encouraging results in Hepatitis C study.

Read more »

E-Therapeutics expects to generate a “wealth of data” from clinical trials

E-Therapeutics (LON:ETX) expects to generate a “wealth of data” from a clinical programme focusing on four drug candidates.

Read more »

Inovio yields long-term immune responses from cervical cancer vaccine

Inovio Pharmaceuticals reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.

Read more »